This metabolite contains a PDE selectivity profile comparable to sildenafil and an in vitro potency for PDE5 close to fifty% on the parent drug. Plasma concentrations of the metabolite are somewhere around 40% of those observed for sildenafil, so that the metabolite accounts for approximately 20% of sildenafil’s pharmacologic effects.The concomit